Scientists develop portable device for detecting circulating tumor cells

NewsGuard 100/100 Score

Researchers at the URV's Department of Physical and Inorganic Chemistry, led by the ICREA researcher, Ramon Álvarez Puebla, and the professor of Applied Physics, Francesc Díaz, and the Department of Clinical Oncology of the HM Torrelodones University Hospital, have patented a portable device that can detect tumor cells in blood.

The device counts the number of tumor cells in a blood sample in real time and is thus a highly effective tool for improving the monitoring, treatment, and diagnosis of cancer.

The system has been successfully tested on patients in various stages of breast cancer and could be used to determine the presence of other tumors by analyzing different antibodies in the blood sample.

Patients with cancer, particularly if it has metastasized, need to be constantly monitored during treatment to assess the progress of the disease. This is currently done using imaging techniques and biopsies which are invasive and not always possible. In contrast, the device designed by the URV researchers is highly sensitive and requires no surgery or treatment involving radiation. It is thus a highly useful clinical method because it improves patient quality of life by removing the need for the more invasive traditional procedures.

The device will be a useful tool for accurately determining a patient's level of health because it can monitor cancer quickly, cheaply, effectively and non-invasively. Furthermore, it can assist in the early diagnosis of the disease and monitor tumors more effectively and in a manner that has a less negative effect on patients' bodies.

Two integrated systems

The new device uses two systems in miniature: a flow system and an optical system. The first causes the blood cells to flow in alignment, while the second uses two optic fibers (a laser diode and a photodetector) to analyze the cells and count those which are cancerous and those which are not. The ratio between the two gives an understanding as to how the cancer is progressing.

The device in operation: a fiber optic shines a blue light on the sample, highlighting the cells as they flow from left to right.

This complex system is the result of research published in the Nature group's Scientific Reports and is part of the doctoral thesis by Eric Pedrol, supervised by Jaume Masons and Francesc Díaz, in collaboration with the Department of Clinical Oncology of the HM Torrelodones University Hospital, led by the researcher Eduardo García-Rico.

The device has been jointly patented by the URV, the ICREA, the CTQC, Medcom Advance and Medcom Tech. It has been licensed for commercialization to Medcom Science, a company engaged in the research and development of technologies for diagnosing and treating cancer. At the URV, the technology and the license to Medcom Science have been protected by the URV's Research Exploitation Unit.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Do neighborhood-level disparities in breast cancer–specific survival remain after accounting for individual, tumor, and treatment characteristics?